Navigation Links
Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
Date:3/14/2008

CINCINNATI, March 14 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Senior Vice President and Chief Financial Officer Karl "Buzz" Brenkert, III will participate in the Lehman Brothers Eleventh Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach Hotel in Miami, Florida, March 18-20, 2008. Kendle's presentation is scheduled for Tuesday, March 18 at 2 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

The public is invited to listen to a live webcast of Kendle's presentation at http://www.kendle.com (click on the link provided in the Investor Events & Presentations section) or at http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=Kendle . An archived version can be accessed following Kendle's presentation and will be available through April 18. Slides accompanying the presentation will be available by 9 a.m. Eastern Time on March 18 at http://www.kendle.com in the Investor Events & Presentations section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust
'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kendle Leaders Adopt 10b5-1 Trading Plans
2. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
3. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
4. Kendle to Present at the Wachovia 2008 Healthcare Conference
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
9. Kendle to Present at the UBS Global Life Sciences Conference
10. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
11. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... DUBLIN, September 30, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... With MSD for Long-Term Commercial Supply of Microplasmin -- LEUVEN, Belgium, September 30, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... Spring Harbor, NY -- The story of the double helix,s ... source -- a never-before-read stack of letters to and from ... 1950-76 -- has been uncovered by two professors at the ... (CSHL). The letters both confirm and extend ...
Cached Biology Technology:Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 2Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 3Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 4Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 5Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 6Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 7Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 8ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 2ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 3ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 4ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 5ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 6ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 7ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 8New twists in double helix discovery story are uncovered 2New twists in double helix discovery story are uncovered 3
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... NEW YORK (Nov. 9, 2010) -- Weill Cornell ... $100,000 grants from the Bill & Melinda Gates Foundation ... Explorations, an initiative to encourage bold and unconventional ideas ... to promising and innovative global health research projects conducted ...
... Colo. (Nov. 9, 2010) As dog bites become an increasingly ... are most at risk for bites, that the culprits are usually ... with the second attack often more brutal than the first. ... Durairaj, MD, of the University of Colorado School of Medicine, who ...
... release is available in Spanish . , U.S. ... ways to improve soil on degraded land so it can ... with USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian ... constructed or replacement subsoils and topsoils to build better and ...
Cached Biology News:Gates Foundation continues funding of tuberculosis research at Weill Cornell 2Gates Foundation continues funding of tuberculosis research at Weill Cornell 3Study shows young, unsupervised children most at risk for dog bites 2Improving soil for better lawns and gardens 2
MHC Volumes 1 & 2...
BD IMagnet 1 each...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
... M.W. Turner (1997). • This book ... in the production of high-quality antibodies, ... the standardisation of antibodies and antigens, ... systems, enzyme immunoassays for detecting cell-surface ...
Biology Products: